Dai-ichi Life invests JPY 500m in cancer therapy developer

22 March 2021

Dai-ichi Life has invested JPY 500m ($4.6m) in Noile-Immune Biotech, a Japanese start-up that develops cancer immunotherapy.

Through this investment, the insurer hopes to provide capital support for Noile-Immune's initiatives, which are expected to extend how long cancer patients can continue to lead healthy lives.